Home
Continuing Education
IMPACT Live
MPN TV Network
Ask the Experts
MPN TV Clinical Insights
Allied Health
Login
|
Register
MPN TV – Your Peer Network
The MPN TV Network is a way to learn and interact with your peers. Please submit a question regarding the current video playing (“Ask the Experts”) to the interviewed author to learn more information regarding this video interview conducted within the MPN TV Network. For more information on other tumor types please check out our partner site O
ncology
.TV.
(www.oncology.tv)
Please select a video from the list below.
Is it better to treat early to control the development of symptoms, or wait until symptoms worsen and then start JAK inhibitor therapy?
Ask the Experts
Use the space below to submit your questions to the MPNUniversity.TV Experts. (Login required.)
Question:
Email Address:
Please wait....Submitting your Question!
Related Questions
No related Ask The Experts Q&A available.
Recent Video
|
Most Popular
Specialties :
<All Specialties>
ASH 2013
ASH 2014
Clinical Insights
MPN - General
Myelofibrosis (MF)
Polycythemia Vera (PV)
Search :
MPN Highlights - ASH 2017
Views - 48
Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera (PV)...
Views - 25
The Impact of Phlebotomy and Hydroxyurea on Survival and Risk of Thrombosis among Older Patients with Polycythemia Vera
Views - 54
Validation of the Myelofibrosis Secondary to PV and ET – Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia..
Views - 14
Characteristics of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of JAK2 Inhibitor Ruxolitinib
Views - 25
Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes
Views - 23
Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea
Views - 9
Examining the Treatment Patterns and Blood Counts Among Patients with Polycythemia Vera Treated With Hydroxyurea in the United States: an Analysis...
Views - 15
Patient-Reported Symptom Burden and Peripheral Blood Counts Among Patients with Polycythemia Vera: An Analysis From the REVEAL Study
Views - 11
Sotatercept (ACE-011) Alone and with Ruxolitinib in Patients with MPN-associated Myelofibrosis (MF) and Anemia with Ruxolitinib or Hydroxyurea
Views - 13
Phase I/II Trial of Glasdegib in Patients With Primary or Secondary Myelofibrosis
Views - 106
Phase 3 Trial of Momelotinib versus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib
Views - 70
Phase 3 Trial of Momelotinib versus Ruxolitinib in JAK Inhibitor Naive Patients with Myelofibrosis
Views - 96
Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response
Views - 84
Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes
Views - 253
PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks
Views - 664
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with MDS
Views - 150
HRQoL and Efficacy with Myelofibrosis Patients in the Phase III Persist-1 Trial of Pacritinib Vs BAT
Views - 61
Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell
Views - 227
First Multicenter, Randomized Phase 3 Study in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Alisertib Versus Investigator's Choice
Views - 70
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with AML and High Risk MDS
Views - 83
5-Azacytidine in Combination with Ruxolitinib As Therapy for Patients with Myelodysplastic/Myeloproliferative Neoplasms
Views - 222
Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia
Views - 160
Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated AML
Views - 114
Prognostic Impact of Molecular Mutations in AML and MDS on Allogeneic Hematopoietic Cell Transplant Outcomes: Adverse Impact of TET2 Mutations
Views - 59
Safety of Lenalidomide 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients with Lower-Risk MDS
Views - 22
A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)
Views - 424
SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML
Views - 68
Outcomes in Patients with Myelofibrosis: Pacritinib Vs BAT in the Phase III Persist-1 Trial
Views - 103
PERSIST-1 phase III study of pacritinib versus BAT in PMF, PPV-MF, or PET-MF
Views - 252
Clinical Discussion Regarding Choice of Therapy for Polycythemia Vera (PV)
Views - 280
Clinical Discussion Regarding Polycythemia Vera (PV) and Thrombosis
Views - 664
Biomarker and Surrogate Targets for Successful Therapy in Polycythemia Vera (PV)
Views - 146
How Do You Treat PV Patients That Fail Hydroxyurea (HU)?
Views - 264
What is the Current Standard of Care in Treating Polycythemia Vera (PV)?
Views - 401
What Would You Suggest for a PMF Patient on Ruxolitinib Who Has Refractory Anemia, but Only Modest Spleen/Symptom Response?
Views - 385
Do You Attempt to Correct Cytopenias Before Giving Ruxolitinib?
Views - 144
Are MF Patients with RBC Transfusion-Dependent Anemia Considered Candidates for Ruxolitinib Therapy?
Views - 295
Do MF Patients with Low Platelets Have a Different Disease Course/Burden Relative to Those with Normal/High Platelets?
Views - 150
For an HU-Refractory PV Patient on Ruxolitinib, How Would Your Treat after He/She Progresses to Post-PV MF?
Views - 254
After PV Progression, Which Patients Should Receive Second-Line Ruxolitinib vs Interferon (IFN)?
Views - 301
What Steps Do You Take for Differential Assessment/Treatment of Debilitating Fatigue in Patients with PV?
Views - 80
Does Development of HU-Refractory PV Increase a Patient’s Risk for Thrombosis/Cardiovascular Events? Why?
Views - 86
Would Pregnancy Change the Management of Young Woman with Low-Risk PV? Do You Alter Antithrombotic Therapy?
Views - 60
Should Patients Continue to Receive Anti-Platelet Therapy/Anticoagulation after Progression to Post-PV MF?
Views - 50
Does Baseline Platelet Count Determine the Starting Dose of Ruxolitinib for HU-Refractory/Intolerant PV (Like It Does for MF)?
Views - 337
Should JAK2V617F Allele Burden Be Monitored in Patients with PV?
Views - 381
In Patients with PV, What Clinical Triggers Would Lead You to Perform a Bone Marrow Biopsy?
Views - 163
What Factors Do You Use to Determine If an MF Patient Is, or Is Not, Benefitting from Long-Term Ruxolitinib Treatment?
Views - 295
How Long Do MF Patients Typically Stay on Ruxolitinib Therapy? What Are the Main Reasons for Discontinuation?
Views - 424
How Often Do You Monitor CBC after a Patient Reaches His/Her Stable Ruxolitinib Dose?
Views - 210
Do Post-PV MF and Primary MF have Different Clinical Courses and/or Prognosis?
Views - 339
Is the Rate of MPN Leukemic Transformation (ie, BP-MPN) Affected by Prior Therapy?
Views - 83
Are There Certain Genetic Alterations That May Help Identify Patients at Risk for Imminent Leukemic Transformation?
Views - 59
For Hematopoietic Cell Signal Transducer (HSCT) Candidates with Advancing MF, What are Their Chief Reasons for Electing Not to Undergo Transplant?
Views - 55
Do Patients Ever Present with >5% Peripheral Blasts at Diagnosis?
Views - 129
If Peripheral Blasts Increase While on Ruxolitinib, is That Considered Treatment Failure?
Views - 72
Are There Different Types of Blasts in the Peripheral Blood, and What Do They Mean for a Patient with an MPN?
Views - 125
Do You Routinely Monitor Patients for Signs of Leukemic Transformation (eg, JAK2 Allele Burden)?
Views - 114
Does Progression to Accelerated or Blast-Phase MF Increase Patient's Splenomegaly/ Symptom Burden?
Views - 207
Introduction to the ImpactLive MPN program
Views - 1317
Dr. Claire Harrison Discusses Where We Stand in the MPN Space Today
Views - 220
Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis
Views - 66
The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera
Views - 159
Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea
Views - 89
Dr. Srdan Verstovsek Discusses Approval of Ruxolitinib as a New Therapy for Patients with Polycythemia Vera
Views - 83
Loss of Response While Being Treated with a JAK Inhibitor
Views - 428
Atypical Infections While Being Treated with a JAK Inhibitor
Views - 323
Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis
Views - 309
First Choice of Therapy for (non-MF) MPN Diagnosed Patients.
Views - 853
2nd Line Therapy for Patients Diagnosed with Polycythemia Vera (PV)
Views - 215
Initiating Treatment for Early Stage Myelofibrosis (MF) Disease
Views - 603
Interim Results on Fedratinib - ASH 2013 - Claire Harrison, DM, FRCP
Views - 252
A Pooled Overall Survival Analysis of The COMFORT Studies - ASH 2013 - Claire Harrison, DM, FRCP
Views - 221
Phase II study of a JAK 1 inhibitor (INCB39110) in patients with MF - John Mascarenhas, M.D.
Views - 1374
Modified Dose Escalation of Ruxolitinib: A Feasible Therapeutic Approach in the Management of MF - ASH 2013 - Ramon Tiu, M.D
Views - 487
Inhibition of JAK-STAT Pathway As a Therapeutic Option For MF Associated Pulmonary Hypertension - Ramon Tiu, M.D.
Views - 457
What are the most important factors to consider when selecting ruxolitinib dosage?
Views - 141
What is the standard of care for first-line treatment of JAK (-) MF?
Views - 204
Is it better to treat early to control the development of symptoms, or wait until symptoms worsen and then start JAK inhibitor therapy?
Views - 169
Is JAK inhibitor therapy beneficial in MF patients who have only mild symptoms and minimal splenomegaly?
Views - 119
Typical Duration of Therapy with Ruxolitinib
Views - 652
Reasons People go off Ruxolitinib
Views - 543
Discussion on Combination Treatment Strategies
Views - 159
Discussion on Patients with Anemia who are Being Treated with Ruxolitinib
Views - 310
Treating Patients with Splenomegaly who are Already Anemic
Views - 225
Treating Patients with Ruxolitinib who have High Platelet Counts
Views - 244
Treating Patients with Ruxolitinib who have Low Platelet Counts
Views - 608
Titration with Ruxolitinib – Titrate up or down?
Views - 710
JAK Inhibitors in Patients with Mutated JAK and Wild-type JAK – Equally Efficacious?
Views - 162
Discussion on the Dysregulation of the JAK STAT Pathway
Views - 200
Treatment options for Patients with PMF (wild-type JAK)
Views - 125
Early Signs and Symptoms in MPNs
Views - 458
Main Reasons for Patient Referral to an MPN Specialist
Views - 891
Other Agents Nearing Approval for the Treatment of MPN's
Views - 79
Current Combination Strategies in the Clinical Setting
Views - 43
Best Treatment Approach in Patients with Low-Risk MF
Views - 82
Most Frequent Adverse Reactions in Patients with Ruxolitinib
Views - 71
Therapy Interruption in Patients on Ruxolitinib
Views - 58
Discussion on QOL Issues
Views - 66
Short-Term and Long-Term Concerns in Treating Patients with MF
Views - 236
Discussion on MPN Therapies
Views - 82
Survival Benefit of Ruxolitinib to Best Available Therapy – COMFORT II Trial
Views - 150
New Therapies in Treating MPNs
Views - 75
Discussion on Disease Modifying Therapies
Views - 62
Discussion on QOL Issues
Views - 67
What do Pharmacists Need to Know
Views - 73
Interruption of Therapy with Ruxolitinib
Views - 52
Storing and Handling of Ruxolitinib
Views - 136
Treatment Issues for First Time Patients on Ruxolitinib
Views - 45
Platelet Count and Proper Dosing of Ruxolitinib in New Patients
Views - 68
Titration with Ruxolitinib – Titrate up or down?
Views - 131
Side Effect Profile Issues
Views - 43
Treatment Strategies – Do They Change with Age?
Views - 55
Starting Dose in Patients Who are Frail or Elderly
Views - 65
Process in Determining Starting Dose for Ruxolitinib
Views - 52
Discussion on CYP3A4 Inhibitors and CYP3A4 Inducers
Views - 323
Lifestyle Modifications in Patients Diagnosed with MPNs
Views - 228
Discussion on Eating Patterns in Patients Diagnosed with MPNs
Views - 72
Discussion on Troublesome Symptoms in Patients Diagnosed with MPNs
Views - 103
How do you Address Issues with Pain Management in Patients Diagnosed with MPNs?
Views - 116
How do you Manage Itching in Patients Diagnosed with MPNs?
Views - 131
What Type of Monitoring/Surveillance is Done in Patients Diagnosed with MPNs
Views - 150
Primary Care Physicians – What do They Need to Know?
Views - 67
Primary Care Physicians – When do you Bring in a Specialist?
Views - 46
MPNUniversity.tv is a member of the
Oncology.TV
family of oncology medical education websites. MPNUniversity.tv offers specialists, primary care physicians, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including
interactive
case based presentations), news and information about Myeloproliferative Neoplasms (MPNs).
Privacy Statement
|
Terms Of Use
|
Contact MPNUniversity.tv
|
Copyright 2018 by MPNUniversity.tv Corporation